Two Sigma Advisers’s Crescent Biopharma CBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-32,500
| Closed | -$385K | – | 880 |
|
|
2025
Q4 | $385K | Buy |
+32,500
| New | +$414K | ﹤0.01% | 1881 |
|
|
2024
Q4 | – | Sell |
-2,490
| Closed | -$42.1K | – | 2407 |
|
|
2024
Q3 | $42.1K | Buy |
2,490
+1,402
| +129% | +$29.4K | ﹤0.01% | 2224 |
|
|
2024
Q2 | $30.6K | Buy |
1,088
+795
| +271% | +$82.7K | ﹤0.01% | 2387 |
|
|
2024
Q1 | $87.9K | Sell |
293
-1,361
| -82% | -$407K | ﹤0.01% | 2312 |
|
|
2023
Q4 | $390K | Sell |
1,654
-536
| -24% | -$83.3K | ﹤0.01% | 2013 |
|
|
2023
Q3 | $329K | Sell |
2,190
-2,321
| -51% | -$366K | ﹤0.01% | 1953 |
|
|
2023
Q2 | $785K | Sell |
4,511
-1,434
| -24% | -$240K | ﹤0.01% | 1627 |
|
|
2023
Q1 | $749K | Buy |
5,945
+4,027
| +210% | +$906K | ﹤0.01% | 1770 |
|
|
2022
Q4 | $581K | Sell |
1,918
-151
| -7% | -$22.3K | ﹤0.01% | 1823 |
|
|
2022
Q3 | $114K | Sell |
2,069
-1,105
| -35% | -$79.4K | ﹤0.01% | 2292 |
|
|
2022
Q2 | $190K | Sell |
3,174
-714
| -18% | -$52.9K | ﹤0.01% | 2287 |
|
|
2022
Q1 | $443K | Sell |
3,888
-2,660
| -41% | -$312K | ﹤0.01% | 2043 |
|
|
2021
Q4 | $943K | Buy |
6,548
+338
| +5% | +$61.3K | ﹤0.01% | 1583 |
|
|
2021
Q3 | $1.36M | Sell |
6,210
-880
| -12% | -$186K | ﹤0.01% | 1466 |
|
|
2021
Q2 | $1.65M | Sell |
7,090
-1,743
| -20% | -$444K | ﹤0.01% | 1395 |
|
|
2021
Q1 | $2.66M | Buy |
8,833
+957
| +12% | +$343K | 0.01% | 1133 |
|
|
2020
Q4 | $2.96M | Buy |
7,876
+4,623
| +142% | +$1.62M | 0.01% | 1071 |
|
|
2020
Q3 | $999K | Buy |
3,253
+60
| +2% | +$22.9K | ﹤0.01% | 1495 |
|
|
2020
Q2 | $1.2M | Buy |
3,193
+1,160
| +57% | +$328K | ﹤0.01% | 1489 |
|
|
2020
Q1 | $464K | Buy |
2,033
+1,507
| +287% | +$576K | ﹤0.01% | 1839 |
|
|
2019
Q4 | $278K | Buy |
+526
| New | +$285K | ﹤0.01% | 2087 |
|
Other funds holding CBIO
BI
FFM
VA
FIS
VPC
OM
TCM
VCM